
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **November 2022**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 [Lavie Bio Investor Presentation.](#)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.

(Registrant)

Date: November 14, 2022

By: /s/ Yaron Eldad

Yaron Eldad

Chief Financial Officer

Lavie Bio

Introduction

November 2022



Forward looking statement

This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.



The fork influences the farm



Healthier
food



Sustainable
environment



Productive
agriculture



Better
value



Farmers around the world invest

\$200B

annually in ag inputs to protect
and nurture their crops

\$10B Ag-Biologicals


\$55B Crop Protection
Chemicals

\$135B Chemical
Fertilizers

*The amounts described herein are based on company's estimations

The Ag-Biologicals opportunity

Driving healthier crops, sustainability and productive agriculture



Driving crop productivity to address consumer preferences

- ✓ Sustainable
- ✓ Protect from resistance development
- ✓ New modes of action



Faster Go-to-Market

Cost




Time

Company estimations



Fastest growing ag inputs segment



*Source: Markets and Markets, industry publications, Reportlinker.com

The Ag-Biologicals untapped potential

	Crop Protection & Fertilizers	Ag-Biologicals Today
Sustainability	+	+++
Efficacy	+++	++
Consistency	+++	+
Commercial viability	+++	+



Our Mission




lavie bio

Improve food quality, sustainability
and agriculture productivity **through**
microbiome based ag-biologicals
technology and products




The Power of the Microbiome


Billions of microbes make a difference!



Billions of microbes
integral to plant-related ecosystems
impact the entire plant lifecycle



Surrounding microbes generate
nature's largest **'function bank'** to
the plant growth and development



These microbes act as the
'Live Engine' supporting yield
production in the field

The challenge: Discovering the right microbes and tailoring them for commercial use



Biology Driven Design platform

The microbiome OS



Discovery

Billions > Promising few



Optimization

Promising few > Product



Commercialization

Product > Label Expansion

¹ Lavie Bio holds an exclusive license to use Evogene's MicroBoost AI tech engine for the discovery and development of products in Lavie Bio's field of activity.


² As part of Corteva's investment in Lavie Bio in 2019, Lavie acquired the assets of Taxon Biosciences, including a large microbial collection.





Decoding the natural diversity of genetic functionality

Function-based product discovery & tailoring



Lavie Bio






Next generation Ag-Biologicals



	Crop Protection & Fertilizers	Ag-Biologicals Today	Ag-Biologicals Next generation
Sustainability	+	+++	+++
Efficacy	+++	++	+++
Consistency	+++	+	+++
Commercial viability	+++	+	+++



Lavie Bio product pipeline

Product Program	Product focus	Target market*	Potential expansion*	Discovery	Pre-Development	Development Stage1	Development Stage2	Pre-Commercialization	Product *
 Bio-Stimulants									
Thrivus™ ¹ INOCULANT	Seed treatment, Spring Wheat North America 	25M ACRES wheat North America	500M ACRES						2022
LAV228 Bio-stimulants 2	Seed treatment Soy North America Europe 	120M ACRES corn US, EU	180M ACRES						>2025
 Bio-Pesticides									
LAV311, LAV312 ² Fruit rots	Foliar Fruits & Veg Europe North America  	>\$200M grapes chemicals usage	+\$800M Additional Fruits & Veg						2024
LAV321, LAV322 Downey mildew	Foliar Fruits & Veg Europe North America  	>\$350M grapes chemicals usage	+\$150M Additional Fruits & Veg						2025
LAV431, LAV432 Seedling disease (Pythium)	Seed Treatment, Corn, soy, F&V North America Europe  	>\$500M	<\$200M						>2025
LAV441, LAV442 Bio-Insecticides	Seed Treatment, Corn, foliar soy North America Europe  	>\$1.5B existing traits and chemicals market	<\$500M						>2025



1 More info on slide 13

2 More info on slide 14

* Company estimations

12

¹ More info on slide 13
² More info on slide 14

* Company estimations



Bio-stimulants driving yield advantage


Sales in North America initiated in 2022

2022	2023- 2024*
USA - ND	USA - ND, MT
	Canada - Sasc. Man. AB.

*Expected geographic expansion





Better than Bio-stimulants benchmarks tested




LAV311 & LAV312

Bio-fungicides against Botrytis & fruit rots

Expected launch in
North America in 2024



**Better than ag-biologicals
and potentially comparable to
chemical benchmarks tested**



Different letters indicate significant differences between groups (p values < 0.05)



Established 'End to End' capabilities



Business Model



Direct model

Lavie Bio Product

- End-to-end product development
- Commercialization through direct channels
- Revenues from sales



Collaboration model

Lavie Bio 'tech-inside' product

- Joint product development
- Commercialization through partner's channels
- Revenues from R&D / milestone payments and royalties,



Strategic Partners & Stakeholders



About Corteva Agriscience (NYSE: CTVA)

A global pure-play agriculture company that provides farmers with a complete portfolio – including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability.



Strategic Collaboration

In August 2019, Lavie Bio and Corteva Agriscience entered a multi-year collaboration, mainly focusing on the development of novel ag-biological products for corn and soybean.



Investment

Corteva's investment in Lavie Bio included a \$10 million equity investment along with the exchange of all shares of Corteva's wholly owned subsidiary Taxon Bioscience.



For more info read the press release: https://evogene.com/press_release/corteva-agriscience-to-invest-in-evogenes-agriculture-biologicals-subsiidiary-lavie-bio/

Strategic Partners & Stakeholders



About ICL Group (NYSE: ICL)

A leading global specialty minerals company, which also benefits from commodity upside. The company creates impactful solutions for humanity's sustainability challenges in the global food, agriculture and industrial markets.



Strategic Collaboration

In August 2022, ICL and Lavie Bio entered a multi-year strategic collaboration for the development of novel bio-stimulant products.



Investment

ICL invested \$10 million in Lavie Bio.



For more info read the press release: https://evogene.com/press_release/icl-and-lavie-bio-enter-strategic-collaboration-to-develop-novel-bio-stimulant-products/



We've got
the right
team to
nurture it



Management Team



Guri Oron
| CEO

Leading multi-disciplinary technological organizations in various industries for 25 years. CEO for the past 13 years



Dor Kestecher
| VP Business Development

10+ years of broad experience leading in agriculture product management, strategy, and development



Russel Putland
| EVP Commercial and US General Manager

30+ years of ag commercial leadership roles with 'ground up' experience in large multi-national organizations



Michael Ionesco
| VP Research

Innovative research leader with deep biotechnology, big data and informatics expertise



Amir Bercovitz
| VP Development

Extensive development and product expertise in the ag-biologicals field for 30+ years - led introductions of 5 commercial products

Board of Directors



Ofer Haviv
Chairman of the board Evogene CEO



Frederic C. Beudot
Global Portfolio Leader for Biologicals at Corteva Agriscience™



Elad Aharonson
President of Innovative Ag Solutions for ICL



Trevor Thiessen
Senior agriculture executive, experienced in marketing, sales, and go-to-market





Milestone Roadmap



2022

- **Bio-stimulant for wheat**
initial product sales of 'Thrivus™' for spring wheat
- **Fruit rot bio-fungicides**
Product candidate advancement in regulation process for LAV311



2023-2024

- **Bio-stimulant for wheat** 'Thrivus™'
product sales expansion to MT, MN and Canada for spring wheat
- **Bio-stimulant for wheat** 'Thrivus™'
label expansion
- **Downy mildew bio-fungicides** File for regulatory approval for leading product candidates LAV321 or LAV322
- Additional product launch



Thank you!
